Caroline Dahlqvist
Research Subjects
Caroline Dahlqvist has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Sebahat Ocak
Division of Pulmonology, CHU UCL Namur (Godinne Site), Université catholique de Louvain (UcL), Yvoir, Namur, Belgium
3 shared publications- Anne-Sophie Dincq
Department of Anaesthesiology, CHU UCL Namur (Godinne Site), Université catholique de Louvain (UcL), Yvoir, Namur, Belgium
2 shared publications - Benjamin Bondue
Department of Pneumology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
2 shared publications - Christophe Compere
CHIREC Hospital, Brussels, Belgium
2 shared publications - Hans Slabbynck
Department of Respiratory Medicine, ZNA Middelheim, Antwerp, Belgium
2 shared publications Jean-Paul D’oDémont
Division of Pulmonology, CHU UCL Namur (Godinne Site), Université catholique de Louvain (UcL), Yvoir, Namur, Belgium
2 shared publications
Latest Publications
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA683
Use of telomere length in the management of idiopathic pulmonary fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) relates to cellular senescence. Telomere shortening, a marker of cellular ageing, is associated with poor outcome in IPF. In the present study, we aimed to analyse the links between telomere length (TL) measured by Flow-FISH, pulmonary function tests and the presence of a telomere-related gene mutation in a real life IPF population. Methods: We included IPF patients from two Belgian academic hospitals and collected all relevant demographical and clinical data. We measured TL by Flow-FISH and expressed it as percentile. We chose the 10th percentile as a threshold for having short telomeres. We looked for an association between TL and lung function decline, familial fibrosis and the presence of a genetic variant. Results: We included 143 patients (106 men, 74%), median age 70. 93% received antifibrotics. Thirty (21%) fulfilled the ERS definition for familial fibrosis. 74 patients (52%) had short telomeres, including 42 (29%) with very short (<P2.5) telomeres. Short TL was associated with male sex (P5% FVC decline at 24 months after diagnosis (OR 2.2, P<0.05). 24-months FVC and DLCO decline were higher in patients with short TL (−4% vs +1% for FVC, P<0.05; -9% vs -4% for DLCO, P<0.05). The association between short TL and FVC decline was age-related and was mostly significant under the age of 75. Patients with familial fibrosis did not have a shorter TL but having short TL was associated with the presence of a genetic variant (P<0.05). Conclusion: Our study confirms the association of short TL and IPF, both sporadic and familial. TL is a predictive biomarker for outcome and the identification of a mutation.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA683
Use of telomere length in the management of idiopathic pulmonary fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) relates to cellular senescence. Telomere shortening, a marker of cellular ageing, is associated with poor outcome in IPF. In the present study, we aimed to analyse the links between telomere length (TL) measured by Flow-FISH, pulmonary function tests and the presence of a telomere-related gene mutation in a real life IPF population. Methods: We included IPF patients from two Belgian academic hospitals and collected all relevant demographical and clinical data. We measured TL by Flow-FISH and expressed it as percentile. We chose the 10th percentile as a threshold for having short telomeres. We looked for an association between TL and lung function decline, familial fibrosis and the presence of a genetic variant. Results: We included 143 patients (106 men, 74%), median age 70. 93% received antifibrotics. Thirty (21%) fulfilled the ERS definition for familial fibrosis. 74 patients (52%) had short telomeres, including 42 (29%) with very short (<P2.5) telomeres. Short TL was associated with male sex (P5% FVC decline at 24 months after diagnosis (OR 2.2, P<0.05). 24-months FVC and DLCO decline were higher in patients with short TL (−4% vs +1% for FVC, P<0.05; -9% vs -4% for DLCO, P<0.05). The association between short TL and FVC decline was age-related and was mostly significant under the age of 75. Patients with familial fibrosis did not have a shorter TL but having short TL was associated with the presence of a genetic variant (P<0.05). Conclusion: Our study confirms the association of short TL and IPF, both sporadic and familial. TL is a predictive biomarker for outcome and the identification of a mutation.
- Open Access
- 2 November 2023
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 46, 101946
Sartan-induced interstitial lung disease
- 2 November 2023
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 46, 101946
Open AccessSartan-induced interstitial lung disease
- Open Access
Treatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease
Background: Interstitial lung disease (ILD) is associated with a higher lung cancer (LC) risk and may impact cancer’s clinical characteristics, treatment strategies, and outcomes. This impact’s extent is unclear, particularly in Caucasians. Methods: In this retrospective observational study, we reviewed the files of all LC patients diagnosed in a 38-month period. Expert radiologists reviewed the computed tomography scans performed at diagnosis. Patients with LC and ILD (n = 29, 7%) were compared to those without ILD (n = 363, 93%) for population and cancer characteristics, treatments, and clinical outcomes. Results: Patients with LC and ILD were older (73 ± 8 vs. 65 ± 11 years; p < 0.001). There was no significant difference in LC histology, localization, stage, or treatment modalities. The respiratory complication rate after cancer treatment was significantly higher in the ILD group (39% vs. 6%; p < 0.01). Overall survival rates were similar at 12 (52% vs. 59%; p = 0.48) and 24 months (41% vs. 45%; p = 0.64) but poorer in the ILD group at 36 months, although not statistically significant (9% vs. 39%; p = 0.06). The ILD group had a higher probability of death (hazard ratio (HR) = 1.49 [0.96;2.27]), but this was not statistically significant (p = 0.06). In a Cox regression model, patients with ILD treated surgically had a significantly higher mortality risk (HR = 2.37 [1.1;5.09]; p = 0.03). Conclusions: Patients with combined LC and ILD have worse clinical outcomes even when similar treatment modalities are offered.
Open AccessTreatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease
Background: Interstitial lung disease (ILD) is associated with a higher lung cancer (LC) risk and may impact cancer’s clinical characteristics, treatment strategies, and outcomes. This impact’s extent is unclear, particularly in Caucasians. Methods: In this retrospective observational study, we reviewed the files of all LC patients diagnosed in a 38-month period. Expert radiologists reviewed the computed tomography scans performed at diagnosis. Patients with LC and ILD (n = 29, 7%) were compared to those without ILD (n = 363, 93%) for population and cancer characteristics, treatments, and clinical outcomes. Results: Patients with LC and ILD were older (73 ± 8 vs. 65 ± 11 years; p < 0.001). There was no significant difference in LC histology, localization, stage, or treatment modalities. The respiratory complication rate after cancer treatment was significantly higher in the ILD group (39% vs. 6%; p < 0.01). Overall survival rates were similar at 12 (52% vs. 59%; p = 0.48) and 24 months (41% vs. 45%; p = 0.64) but poorer in the ILD group at 36 months, although not statistically significant (9% vs. 39%; p = 0.06). The ILD group had a higher probability of death (hazard ratio (HR) = 1.49 [0.96;2.27]), but this was not statistically significant (p = 0.06). In a Cox regression model, patients with ILD treated surgically had a significantly higher mortality risk (HR = 2.37 [1.1;5.09]; p = 0.03). Conclusions: Patients with combined LC and ILD have worse clinical outcomes even when similar treatment modalities are offered.
- Open Access
- 16 April 2022
- Published by Springer Nature in Pulmonary Therapy
- Vol. 8 (2) , 181-194
Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
Introduction The PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL) outcomes, healthcare resource use (HCRU), and the association between QoL and mortality in patients enrolled in the PROOF registry are presented. Methods QoL outcomes (St. George’s Respiratory Questionnaire [SGRQ], EuroQoL-5 dimensions-5 levels Health Questionnaire [EQ-5D-5L], EuroQoL-5 dimensions Health Questionnaire [EQ-5D] visual analogue scale [VAS] and cough VAS) and HCRU were collected for all patients. Associations between baseline QoL and mortality were assessed using univariate and multivariate analyses. During multivariate analyses, individual QoL measures were adjusted for the following covariates: age, sex, percent predicted forced vital capacity, percent predicted diffusing capacity of the lungs for carbon monoxide, smoking status, and supplementary oxygen use at registry inclusion. Results In total, 277 patients were enrolled in the PROOF registry. During the follow-up period, worsening in cough VAS score, SGRQ symptom score, and SGRQ activity score was observed, while EQ-5D VAS, SGRQ total score, and SGRQ impact score remained stable. During univariate analyses, EQ-5D VAS and all SGRQ sub-scores and total score at baseline were associated with mortality; however, during multivariate analyses, only the SGRQ total score, SGRQ impact score, and SGRQ symptom score at baseline were associated with mortality. During the follow-up period, 261 (94.2%) patients required an outpatient consultation (IPF- or non-IPF-related) and there were 182 hospitalizations in total, most of which were respiratory related (66.5%). Conclusions The PROOF registry provided valuable, real-world data on the association between baseline QoL and mortality, and longitudinal HCRU and QoL outcomes in patients with IPF over 24 months and identified that SGRQ may be an independent prognostic factor in IPF.
- 16 April 2022
- Published by Springer Nature in Pulmonary Therapy
- Vol. 8 (2) , 181-194
Open AccessQuality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry
Introduction The PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL) outcomes, healthcare resource use (HCRU), and the association between QoL and mortality in patients enrolled in the PROOF registry are presented. Methods QoL outcomes (St. George’s Respiratory Questionnaire [SGRQ], EuroQoL-5 dimensions-5 levels Health Questionnaire [EQ-5D-5L], EuroQoL-5 dimensions Health Questionnaire [EQ-5D] visual analogue scale [VAS] and cough VAS) and HCRU were collected for all patients. Associations between baseline QoL and mortality were assessed using univariate and multivariate analyses. During multivariate analyses, individual QoL measures were adjusted for the following covariates: age, sex, percent predicted forced vital capacity, percent predicted diffusing capacity of the lungs for carbon monoxide, smoking status, and supplementary oxygen use at registry inclusion. Results In total, 277 patients were enrolled in the PROOF registry. During the follow-up period, worsening in cough VAS score, SGRQ symptom score, and SGRQ activity score was observed, while EQ-5D VAS, SGRQ total score, and SGRQ impact score remained stable. During univariate analyses, EQ-5D VAS and all SGRQ sub-scores and total score at baseline were associated with mortality; however, during multivariate analyses, only the SGRQ total score, SGRQ impact score, and SGRQ symptom score at baseline were associated with mortality. During the follow-up period, 261 (94.2%) patients required an outpatient consultation (IPF- or non-IPF-related) and there were 182 hospitalizations in total, most of which were respiratory related (66.5%). Conclusions The PROOF registry provided valuable, real-world data on the association between baseline QoL and mortality, and longitudinal HCRU and QoL outcomes in patients with IPF over 24 months and identified that SGRQ may be an independent prognostic factor in IPF.
- Open Access
- 1 January 2020
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 31, 101141
Secondary organizing pneumonia associated with sertraline: A case report
- 1 January 2020
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 31, 101141
Open AccessSecondary organizing pneumonia associated with sertraline: A case report
- Open Access
- 24 October 2019
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 1-12
Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
Background: The PROOF registry is an observational study initiated in October 2013 with the aim to monitor disease progression in a real-world population of patients with idiopathic pulmonary fibrosis (IPF). Here, we present longitudinal clinical outcomes from the PROOF registry. Methods: Patients with IPF were enrolled across eight centers in Belgium and Luxembourg. For all patients, clinical outcomes data were collected, including mortality, lung transplant, acute exacerbations, and pulmonary hypertension. For patients treated with pirfenidone at any time during follow-up (2013–2017), for any duration of treatment (the pirfenidone-treated population): pirfenidone treatment patterns were collected; changes in pulmonary function (forced vital capacity [FVC] and carbon monoxide diffusing capacity [DLco]) were reviewed up to 24 months post-inclusion; and time-to-event analyses from the time of registry inclusion were performed. Results: The PROOF registry enrolled a total of 277 patients. During follow-up, 23.1% of patients died, 5.1% received a lung transplant, 5.4% experienced an acute exacerbation, and 6.1% had comorbid pulmonary hypertension. In the pirfenidone-treated population (N = 233, 84.1%), 12.9% of patients had a temporary dose discontinuation and 31.8% had a temporary dose reduction; 4.3% of patients permanently discontinued pirfenidone due to an adverse drug reaction. Mean percent predicted FVC was 81.2% (standard deviation [SD] 19.0) at Month 0 and 78.3% (SD 25.0) at Month 24, and mean percent predicted DLco was 47.0% (SD 13.2) and 45.0% (SD 16.5), respectively. Rates of ≥ 10% absolute decline in percent predicted FVC and ≥ 15% absolute decline in percent predicted DLco over 24 months were 31.0% and 23.2%, respectively. Mean times from registry inclusion to categorical absolute decline in percent predicted FVC and percent predicted DLco were 20.1 (standard error [SE] 0.6) months and 23.4 (SE 0.5) months, respectively; mean time from registry inclusion to death was 31.0 (SE 0.9) months. Conclusions: The PROOF registry is a source of European data characterizing longitudinal clinical outcomes of patients with IPF. Over 12 months of follow-up, pulmonary function remained largely stable in patients with IPF who received pirfenidone for any duration of treatment. Pulmonary function remained similar at 24 months of follow-up, although patient numbers were lower. Trial registration: PROOF is registered with the relevant authorities in Belgium and Luxembourg, with registration to Comité National d’Éthique et de Recherche (CNER) N201309/03–12 September 2013 and a notification to Comité National de Protection des Données (CNDP) for Luxembourg.
- 24 October 2019
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 1-12
Open AccessLongitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
Background: The PROOF registry is an observational study initiated in October 2013 with the aim to monitor disease progression in a real-world population of patients with idiopathic pulmonary fibrosis (IPF). Here, we present longitudinal clinical outcomes from the PROOF registry. Methods: Patients with IPF were enrolled across eight centers in Belgium and Luxembourg. For all patients, clinical outcomes data were collected, including mortality, lung transplant, acute exacerbations, and pulmonary hypertension. For patients treated with pirfenidone at any time during follow-up (2013–2017), for any duration of treatment (the pirfenidone-treated population): pirfenidone treatment patterns were collected; changes in pulmonary function (forced vital capacity [FVC] and carbon monoxide diffusing capacity [DLco]) were reviewed up to 24 months post-inclusion; and time-to-event analyses from the time of registry inclusion were performed. Results: The PROOF registry enrolled a total of 277 patients. During follow-up, 23.1% of patients died, 5.1% received a lung transplant, 5.4% experienced an acute exacerbation, and 6.1% had comorbid pulmonary hypertension. In the pirfenidone-treated population (N = 233, 84.1%), 12.9% of patients had a temporary dose discontinuation and 31.8% had a temporary dose reduction; 4.3% of patients permanently discontinued pirfenidone due to an adverse drug reaction. Mean percent predicted FVC was 81.2% (standard deviation [SD] 19.0) at Month 0 and 78.3% (SD 25.0) at Month 24, and mean percent predicted DLco was 47.0% (SD 13.2) and 45.0% (SD 16.5), respectively. Rates of ≥ 10% absolute decline in percent predicted FVC and ≥ 15% absolute decline in percent predicted DLco over 24 months were 31.0% and 23.2%, respectively. Mean times from registry inclusion to categorical absolute decline in percent predicted FVC and percent predicted DLco were 20.1 (standard error [SE] 0.6) months and 23.4 (SE 0.5) months, respectively; mean time from registry inclusion to death was 31.0 (SE 0.9) months. Conclusions: The PROOF registry is a source of European data characterizing longitudinal clinical outcomes of patients with IPF. Over 12 months of follow-up, pulmonary function remained largely stable in patients with IPF who received pirfenidone for any duration of treatment. Pulmonary function remained similar at 24 months of follow-up, although patient numbers were lower. Trial registration: PROOF is registered with the relevant authorities in Belgium and Luxembourg, with registration to Comité National d’Éthique et de Recherche (CNER) N201309/03–12 September 2013 and a notification to Comité National de Protection des Données (CNDP) for Luxembourg.
- Open Access
- 22 May 2018
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2018, 1
Corrigendum to “Fully Covered Metallic Stents for the Treatment of Benign Airway Stenosis”
[This corrects the article DOI: 10.1155/2016/8085216.].
- 22 May 2018
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2018, 1
Open AccessCorrigendum to “Fully Covered Metallic Stents for the Treatment of Benign Airway Stenosis”
[This corrects the article DOI: 10.1155/2016/8085216.].
- Open Access
- 29 September 2016
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2016, 1-7
Fully Covered Metallic Stents for the Treatment of Benign Airway Stenosis
Introduction.We herein report our experience with new fully covered self-expanding metallic stents in the setting of inoperable recurrent benign tracheobronchial stenosis.Methods.Between May 2010 and July 2014, 21 Micro-Tech® FC-SEMS (Nanjing Co., Republic of Korea) were placed in our hospital in 16 patients for inoperable, recurrent (after dilatation), and symptomatic benign airway stenosis. Their medical files were retrospectively reviewed in December 2014, with focus on stent’s tolerance and durability data.Results.Twenty-one stents were inserted: 13 for posttransplant left main bronchus anastomotic stricture, seven for postintubation tracheal stenosis, and one for postlobectomy anastomotic stricture. Positioning was easy for all of them. Stents were in place for a mean duration of 282 days. The most common complications were granulation tissue development (35%), migration (30%), and sputum retention (15%). Fifty-five % of the stents (11/20) had to be removed because of various complications, without difficulty for all of them. None of the patients had life-threatening complications.Conclusion.Micro-Tech FC-SEMS were easy to position and to remove. While the rate of complications requiring stent removal was significant, no life-threatening complication occurred. Further studies are needed to better define their efficacy and safety in the treatment of benign airway disease.
- 29 September 2016
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2016, 1-7
Open AccessFully Covered Metallic Stents for the Treatment of Benign Airway Stenosis
Introduction.We herein report our experience with new fully covered self-expanding metallic stents in the setting of inoperable recurrent benign tracheobronchial stenosis.Methods.Between May 2010 and July 2014, 21 Micro-Tech® FC-SEMS (Nanjing Co., Republic of Korea) were placed in our hospital in 16 patients for inoperable, recurrent (after dilatation), and symptomatic benign airway stenosis. Their medical files were retrospectively reviewed in December 2014, with focus on stent’s tolerance and durability data.Results.Twenty-one stents were inserted: 13 for posttransplant left main bronchus anastomotic stricture, seven for postintubation tracheal stenosis, and one for postlobectomy anastomotic stricture. Positioning was easy for all of them. Stents were in place for a mean duration of 282 days. The most common complications were granulation tissue development (35%), migration (30%), and sputum retention (15%). Fifty-five % of the stents (11/20) had to be removed because of various complications, without difficulty for all of them. None of the patients had life-threatening complications.Conclusion.Micro-Tech FC-SEMS were easy to position and to remove. While the rate of complications requiring stent removal was significant, no life-threatening complication occurred. Further studies are needed to better define their efficacy and safety in the treatment of benign airway disease.